|Bid||1.6800 x 900|
|Ask||1.6900 x 36900|
|Day's Range||1.6550 - 1.7250|
|52 Week Range||1.6000 - 3.5700|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 2, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
If you own shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) then it's worth thinking about how it contributes to...
Altria Group Inc. (MO), BioMarin Pharmaceutical Inc. (BMRN), Pennant Park Investment Corp. (PNNT), and Rigel Pharmaceuticals Inc. (RIGL) have declined to their three-year lows Continue reading...
SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled ...
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Rigel (RIGL) delivered earnings and revenue surprises of 14.29% and 12.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
TAVALISSE® net product sales increased 26% quarter over quarter to $10.2 million First patients enrolled in Phase 3 pivotal trial of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) Conference call ...
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
SOUTH SAN FRANCISCO , July 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2019 financial results after market close on Tuesday, ...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters ...
SOUTH SAN FRANCISCO, Calif. , May 31, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present ...
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA). "Enrolling the first patient in our Phase 3 clinical trial of fostamatinib in warm AIHA is an important milestone in our efforts to develop the first FDA-approved therapy for this disease," stated Raul Rodriguez, president and CEO.
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...